Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation

Clinical and Experimental Immunology

Volumn 156, Issue 1, 2009, Pages 141-148

  Roelen, D L ^a   Huurman, V A L ^a   Hilbrands, R ^b   Gillard, P ^b,c   Duinkerken, G ^a   Van Der Meer Prins, P W M ^a   Versteeg Van Der Voort Maarschalk, M F J ^a   Mathieu, C ^c   Keymeulen, B ^b   Pipeleers, D G ^b   Roep, B O ^a   Claas, F H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cell transplantation; Autoimmunity; Cytotoxic T cell; Islets of Langerhans; Type 1 diabetes

Indexed keywords

C PEPTIDE; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOIMMUNITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AUTOIMMUNITY; C-PEPTIDE; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE CARE; SIROLIMUS; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 61849097838     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03812.x     Document Type: Article

References (38)

1. Sutherland DE, Gruessner RW, Dunn DL et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001 233 : 463 501.
2. Smets YF, Westendorp RG, van der Pijl JW et al. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 1999 353 : 1915 9.
3. Gaglia JL, Shapiro AM, Weir GC. Islet transplantation: progress and challenge. Arch Med Res 2005 36 : 273 80.
4. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 343 : 230 8.
5. Keymeulen B, Ling Z, Gorus FK et al. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998 41 : 452 9.
6. Hering BJ, Kandaswamy R, Harmon JV et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004 4 : 390 401.
7. Ricordi C, Inverardi L, Kenyon NS, Goss J, Bertuzzi F, Alejandro R. Requirements for success in clinical islet transplantation. Transplantation 2005 79 : 1298 300.
8. Keymeulen B, Gillard P, Mathieu C et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA 2006 103 : 17444 9.
9. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005 54 : 2060 9.
10. Gillard P, Ling Z, Mathieu C et al. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 2008 85 : 256 63.
11. Maes BD, Kuypers D, Messiaen T et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001 72 : 1655 61.
12. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000 35 : 333 46.
13. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999 5 : 1298 302.
14. van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003 75 : 788 91.
15. Fraenkel M, Ketzinel-Gilad M, Ariav Y et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008 57 : 945 57.
16. Zhang N, Su D, Qu S et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006 55 : 2429 36.
17. van de Linde P, van de Boog P, Tysma OMH et al. Immunotherapy with antibodies to protect beta cells in type I diabetic pancreas transplant recipients. Clin Exp Immunol 2007 149 : 56 62.
18. Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002 360 : 1662 4.
19. Huurman VAL, Hilbrands R., Pinkse GGM et al. Cellular islet autoimmunity associates with clinical outcome of islet transplantation. PLoS ONE 2008 3 : e2435.
20. Roep BO, Stobbe I, Duinkerken G et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999 48 : 484 90.
21. van Kampen CA, van de Linde P, Duinkerken G et al. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005 80 : 118 26.
22. Heemskerk MB, Roelen DL, Dankers MK et al. Allogeneic MHC class I molecules with numerous sequence differences do not elicit a CTL response. Hum Immunol 2005 66 : 969 76.
23. Maleux G, Gillard P, Keymeulen B et al. Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. J Vasc Interv Radiol 2005 16 : 1693 7.
24. Movahedi B, Keymeulen B, Lauwers MH, Goes E, Cools N, Delvaux G. Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. Transplant Int 2003 16 : 186 90.
25. Roep BO, Kallan AA, Duinkerken G et al. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes 1995 44 : 278 83.
26. Bouma GJ, van der Meer-Prins PM, van Bree FP, van Rood JJ, Claas FH. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol 1992 35 : 85 92.
27. Strijbosch LW, Does RJ, Buurman WA. Computer aided design and evaluation of limiting and serial dilution experiments. Int J Biomed Comput 1988 23 : 279 90.
28. Hu H, Dong Y, Feng P, Fechner J, Hamawy M, Knechtle SJ. Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. Transplantation 2003 75 : 1075 7.
29. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005 5 : 465 74.
30. Lee YR, Yang IH, Lee YH et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005 105 : 3951 5.
31. Lee YH, Lee YR, Im SA et al. Calcineurin inhibitors block MHC-restricted antigen presentation in vivo. J Immunol 2007 179 : 5711 6.
32. Naranjo-Gómez M, Climent N, Cos J et al. Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion. Immunology 2006 119 : 488 98.
33. Roelen D, Datema G, van Bree S, Zhang L, van Rood J, Claas F. Evidence that antibody formation against a certain HLA alloantigen is associated not with a quantitative but with a qualitative change in the cytotoxic T cells recognizing the same antigen. Transplantation 1992 53 : 899 903.
34. Roelen DL, van Bree S, Witvliet MD et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation 1994 57 : 1388 92.
35. van Kampen CA, Versteeg-van der Voort Maarschalk MF, Roelen DL, ten Berge IJ, Claas FH. Rejection of a kidney transplant does not always lead to priming of cytotoxic T cells against mismatched donor HLA class I antigens. Transplantation 2001 71 : 869 74.
36. Cantaluppi V, Biancone L, Romanazzi GM et al. Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 2006 6 : 2601 11.
37. Battaglia M, Stabilini A, Draghici E et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 2006 55 : 1571 80.
38. Battaglia M, Stabilini A, Draghici E et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006 55 : 40 9.